KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $12.1 billion.

  • Moderna's Liabilities and Shareholders Equity fell 23.21% to $12.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $51.0 billion, marking a year-over-year decrease of 23.48%. This contributed to the annual value of $14.1 billion for FY2024, which is 23.25% down from last year.
  • Moderna's Liabilities and Shareholders Equity amounted to $12.1 billion in Q3 2025, which was up 1.04% from $12.0 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Liabilities and Shareholders Equity ranged from a high of $27.6 billion in Q1 2022 and a low of $12.0 billion during Q2 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $15.8 billion (2024), whereas its average is $16.6 billion.
  • As far as peak fluctuations go, Moderna's Liabilities and Shareholders Equity skyrocketed by 513.97% in 2021, and later tumbled by 30.66% in 2024.
  • Over the past 5 years, Moderna's Liabilities and Shareholders Equity (Quarterly) stood at $24.7 billion in 2021, then grew by 4.82% to $25.9 billion in 2022, then declined by 28.74% to $18.4 billion in 2023, then decreased by 23.25% to $14.1 billion in 2024, then decreased by 23.21% to $12.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $12.1 billion in Q3 2025, compared to $12.0 billion in Q2 2025 and $12.7 billion in Q1 2025.